Considered and approved Un-audited Financial results of the Company for the Third Quarter and Nine Months ended December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals reported a sharp jump in Q3 FY26 revenue from operations at Rs. 39.13 crore, up from Rs. 10.58 crore in Q3 FY25 — a roughly 270% year-on-year surge. For the nine months ended December 2025, revenue stood at Rs. 50.40 crore versus Rs. 19.32 crore in the same period last year, an increase of around 161%. Net profit for the quarter was Rs. 20.36 crore (vs Rs. 3.16 crore) and for nine months was Rs. 23.77 crore (vs Rs. 4.19 crore), translating to PAT growth of well over 400% on a nine-month basis. The board also re-appointed Mr. Dakshesh Shah as Managing Director for a fresh 5-year term from December 30, 2025 to December 30, 2030. Statutory auditors Shah Sanghvi & Associates issued an unqualified limited review report on both standalone and consolidated results; the consolidated figures include five subsidiaries that contributed nil revenue and nil profit.
Very strong quarter with revenue and profit both jumping several-fold year-on-year, suggesting a major scale-up in the business — potentially positive for the stock, though investors should watch whether this growth rate is sustainable given the small base.